Log In
BCIQ
Print this Print this
 

delanzomib (CEP-18770)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionProteasome inhibitor
Molecular Target Proteasome
Mechanism of ActionProteasome inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today